On September 4, 2025, the US Food and Drug Administration (FDA or the Agency) announced that it released a second batch of complete response letters (CRLs) — which explain the Agency’s determination ...
The issues addressed in these letters are usually related to "safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues." HealthDay News — The US Food and Drug Administration ...
The FDA has issued a second complete response letter to Atara Biotherapeutics for its biologicals license application of ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
NOVATO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) ...
On July 10, 2025, in the name of embracing “radical transparency,” the U.S. Food and Drug Administration (“FDA”) announced that it was publishing more than 200 complete response letters (“CRLs”) 1 ...
The U.S. Food and Drug Administration (FDA) on Thursday published more than 200 complete response letters ((CRLs)), through which drugmakers are informed about the agency’s rejections of their ...
When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided an in-depth view into the high-stakes discussions that decide whether a medicine will ever make ...
The next time the FDA turns down a drug application, the letter outlining the decision and the regulator’s reasoning will become public record. The agency said it will release future complete response ...
The goal is to improve public understanding of the FDA decision-making process. (HealthDay News) — The U.S. Food and Drug Administration has published more than 200 complete response letters, or ...
Ultragenyx received a Complete Response Letter from the FDA regarding its UX111 therapy for Sanfilippo syndrome type A, citing manufacturing observations. Ultragenyx Pharmaceutical Inc. announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results